Grassley questions profits from discount drug program

ADVERTISEMENT
The paper reported that 67 percent of Duke's 340B patients had commercial healthcare coverage, while only five percent were uninsured.

In a letter to federal health officials last week, Grassley questioned whether the program intended hospitals to sell 340B drugs to non-charity patients for large profits.

"These numbers paint a very stark picture of how hospitals are reaping sizeable 340B discounts on drugs and then turning around and up-selling them to fully insured patients … in order to maximize their spread," Grassley wrote in a letter to the Health Resources and Services Administration (HRSA), which oversees the 340B program.

Grassley's probe began in September after reporters in Raleigh and Charlotte found that large non-profit hospitals were inflating the price of cancer drugs.

In addition to Duke University Hospital, he also questioned UNC Hospitals and Carolinas Medical Center.

“If ‘non-profit’ hospitals are essentially profiting from the 340B program without passing those savings to its patients, then the 340B program is not functioning as intended,” Grassley wrote to the hospitals.


More in Healthcare

Separate and unequal — ACA and the safety net

Read more »